AbbVie (NYSE:ABBV) Sets New 52-Week High – Here’s Why

AbbVie Inc. (NYSE:ABBV) hit a new 52-week high during mid-day trading on Thursday . The company traded as high as $258.45 and last traded at $259.20, with a volume of 817884 shares changing hands. The stock had previously closed at $251.06.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie’s recent acquisition of Apogee Therapeutics is being viewed as a strategically accretive deal that could widen its already strong moat and support longer-term pipeline growth. AbbVie: Apogee Deal Just Widened An Already Dominant Moat
• Positive Sentiment: AbbVie highlighted milestone data for venetoclax in chronic lymphocytic leukemia, reinforcing confidence in its oncology portfolio and the durability of one of its key franchises. AbbVie Inc. (ABBV) Hits New Milestone with Venetoclax on Chronic Lymphocytic Leukemia (CLL) Treatment
• Positive Sentiment: Analysts and market commentary continue to point to AbbVie’s beat-and-raise track record, dividend strength, and pipeline expansion as reasons the stock deserves a premium valuation. J&J or AbbVie: Which Stock Deserves a Place in Your Portfolio Now?
• Positive Sentiment: AbbVie and Genmab reported encouraging lymphoma trial results, which could expand the opportunity for Epkinly and support additional label growth. Genmab/AbbVie Lymphoma Trial Meets Main Goal, Analyst Eyes Bigger Market Opportunity
• Neutral Sentiment: AbbVie remains part of broader dividend-stock and healthcare-stock commentary, which supports a positive investor tone but does not add a major new catalyst on its own. 3 Dividend Stocks to Buy Hand Over Fist in July
• Negative Sentiment: Erste Group trimmed its FY2027 EPS estimate slightly, suggesting some analysts still see modest pressure on AbbVie’s earnings outlook despite the recent rally. What Sparked the $43B Jump in AbbVie’s Market Cap in the Past Week?
• Negative Sentiment: News that U.S. lawmakers are probing AbbVie’s China clinical-trial activities could create headline risk and raise investor concerns around regulatory and geopolitical exposure. Merck, AbbVie probed by US lawmakers over China clinical trials: report

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on ABBV shares. Wells Fargo & Company set a $260.00 price target on AbbVie in a research note on Monday, June 22nd. BMO Capital Markets restated an “outperform” rating on shares of AbbVie in a report on Monday, March 9th. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of AbbVie in a research report on Tuesday, June 23rd. Canaccord Genuity Group upped their price target on AbbVie from $265.00 to $273.00 and gave the stock a “buy” rating in a report on Tuesday, June 23rd. Finally, Morgan Stanley increased their price target on AbbVie from $270.00 to $278.00 and gave the company an “overweight” rating in a research report on Thursday, April 30th. Three analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, AbbVie currently has a consensus rating of “Moderate Buy” and an average target price of $253.81.

AbbVie Price Performance

The firm has a fifty day simple moving average of $217.86 and a two-hundred day simple moving average of $219.76. The firm has a market capitalization of $458.19 billion, a P/E ratio of 127.85, a price-to-earnings-growth ratio of 0.83 and a beta of 0.32.

AbbVie (NYSE:ABBV) last issued its earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.59 by $0.06. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The firm had revenue of $15 billion for the quarter, compared to analyst estimates of $14.72 billion. During the same period in the previous year, the company posted $2.46 earnings per share. The business’s revenue was up 12.4% on a year-over-year basis. On average, research analysts anticipate that AbbVie Inc. will post 14.28 EPS for the current year.

AbbVie Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, August 14th. Investors of record on Wednesday, July 15th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date is Wednesday, July 15th. AbbVie’s payout ratio is currently 340.89%.

Hedge Funds Weigh In On AbbVie

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Procyon Advisors LLC raised its stake in AbbVie by 19.9% in the fourth quarter. Procyon Advisors LLC now owns 32,752 shares of the company’s stock valued at $7,484,000 after purchasing an additional 5,427 shares in the last quarter. Waycross Partners LLC grew its stake in AbbVie by 2.9% in the 4th quarter. Waycross Partners LLC now owns 182,476 shares of the company’s stock worth $41,694,000 after buying an additional 5,063 shares in the last quarter. Calamos Advisors LLC increased its holdings in shares of AbbVie by 3.4% in the 4th quarter. Calamos Advisors LLC now owns 466,290 shares of the company’s stock worth $106,543,000 after buying an additional 15,458 shares during the last quarter. Wealth Enhancement Advisory Services LLC increased its holdings in shares of AbbVie by 11.7% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 636,710 shares of the company’s stock worth $143,026,000 after buying an additional 66,720 shares during the last quarter. Finally, Axecap Investments LLC raised its position in shares of AbbVie by 713.2% during the 4th quarter. Axecap Investments LLC now owns 16,320 shares of the company’s stock valued at $3,729,000 after buying an additional 14,313 shares in the last quarter. Institutional investors own 70.23% of the company’s stock.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.